Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?

Abstract

Since the advent of modern surgery for pancreatic cancer, clinicians have recognized this cancer's propensity to recur locally, metastasize, and cause death. Despite significant efforts to improve patient outcomes with better adjuvant therapy, only modest gains in survival have been observed. An alternative strategy of neoadjuvant therapy followed by surgery has the potential to improve patient selection and survival, and expand the pool of patients eligible for curative surgery. This article summarizes large, randomized trials of adjuvant therapy, explains the limitations imposed by up-front surgery, and suggests neoadjuvant therapy as a rational alternative to initial surgery and adjuvant therapy.

Keywords: Adjuvant therapy; Borderline resectable pancreatic cancer; Chemotherapy; Locally advanced pancreatic cancer; Neoadjuvant therapy; Preoperative therapy; Resectable pancreatic cancer; Resection.